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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To identify the accuracy of depression rating scales as screening tools for detectingDpD and compare the diagnostic accuracy of different
depression rating scales for detecting MDD among adults with Alzheimer’s disease and related forms of dementia.
To examine factors that may impact on the accuracy of depression rating scales that are used to diagnose depression. We will examine
the reference standard used for verification of DpD, baseline prevalence of DpD in the study population, age of the underlying study
population, gender of participants, type of dementia (any-cause dementia versus Alzheimer’s disease), study setting (community or
primary care setting, long-term care, tertiary care setting), and study country as potential sources of heterogeneity.We will also evaluate
the effects of using different cut-points of individual depression rating scales on the diagnostic accuracy of the scales.
B A C K G R O U N D
Target condition being diagnosed
Dementia currently affects approximately 35.6 million individu-
als worldwide, and the prevalence of dementia is anticipated to
increase to 115 million by the year 2050 (Prince 2013). Depres-
sion has a bidirectional relationship with dementia: individuals
with depression earlier in life have a two-fold increased risk of later
developing dementia (Byers 2011; Byers 2012), and dementia is
associated with six and a half times increased risk of developing
significant symptoms of depression (Chen 1999; Djernes 2006;
Starkstein 2005). As a result of this increased risk, an estimated
20% to 30% of people with Alzheimer’s disease will developmajor
depressive disorder (MDD) (Castilla-Puentes 2010; Enache 2011;
Lyketsos 1997; Weiner 2001). MDD in dementia (DpD) tends
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to be chronic and persistent once it develops during the course of
Alzheimer’s disease (Aalten 2005; Steinberg 2004).
MDD is diagnosed clinically based on assessment by healthcare
providers familiar with diagnostic criteria for MDD. The crite-
ria for MDD in the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5) require the presence of a sin-
gle or recurrent major depressive episode (American Psychiatric
Association 2013). A major depressive episode consists of five or
more symptoms of depression over a two-week period that repre-
sents a change from a previous level of functioning. One of the
symptoms for a major depressive episode must be either depressed
mood (either reported by the patient or observed by others) or
loss of interest or enjoyment in most activities (either reported
by the patient or others). Along with at least one of these two
symptoms, a total of four other symptoms must be present in-
cluding a significant change in weight or appetite, insomnia or
hypersomnia, psychomotor agitation or retardation, fatigue, feel-
ings or worthlessness or guilt, difficulties with concentration, and
recurrent thoughts of death or suicide. The symptoms of MDD
must result in significant distress or difficulties in interpersonal or
role functioning. These symptoms cannot be directly caused by a
general medical condition or be caused by substances. The major
depressive episode inMDD cannot occur as a part of another con-
dition such as bipolar disorder or schizoaffective disorder, which
can also have major depressive episodes. MDD can be further de-
scribed in terms of its severity (mild, moderate, or severe) based
on the number and severity of symptoms and resulting distress or
dysfunction. MDD can also be specified as having the presence or
absence of psychotic features, along with other specifiers for addi-
tional symptomswhichmay be present in the course ofMDDsuch
as anxiety or catatonia. The diagnosis ofMDD in earlier versions of
theDiagnostic and StatisticalManual ofMental Disorders, Fourth
Edition (Text Revision) (DSM-IV-TR) are similar to those pro-
vided in the DSM-5 (American Psychiatric Association 2000), as
are other criteria for MDD such as the International Classification
of Diseases (ICD) (World Health Organization 1992). Specific
criteria for the diagnosis of DpD have also been proposed (Olin
2002). These are similar to the criteria for MDD in populations
without dementia except that only three symptoms of a major de-
pressive episode are required (instead of five symptoms), with one
of the symptoms being either depressedmood or loss of enjoyment
in activities. Depressed mood or loss of enjoyment in activities can
be identified either through patient report or caregiver or clinician
observation of the patient. DpD can be diagnosed using either
generic MDD criteria or criteria specific for DpD.
Clinical practice guidelines, in Canadian Coalition for Seniors’
Mental Health 2006 and Herrmann 2008, and reviews, in Kales
2014, Pieper 2011, Seitz 2012, Seitz 2013, and Sink 2005, recom-
mend that individuals with dementia be assessed for MDD, and
the identification and treatment of DpD is an important part of
providing care for individuals with dementia for several reasons.
Most individuals with DpD are not treated, often due to under-
diagnosis of DpD (Payne 2002; van Asch 2013), and untreated
DpD is associated with increased mortality (Geerlings 1999), ac-
celerated cognitive decline (Hargrave 2000), earlier nursing home
placement (Dorenlot 2005), and decreased quality of life (Winter
2011). Underdiagnosis of DpD can be associated with increased
use of medications such as benzodiazepines and antipsychotics
(Evers 2002; Volicer 2011), while overdiagnosis can lead to the in-
appropriate use of antidepressants (Berman 2012). When DpD is
accurately identified, effective nonpharmacological interventions
for depression can be implemented (McSweeney 2012; Orgeta
2014; Teri 1997; Teri 2003; Teri 2005). The efficacy of pharma-
cological interventions for DpD is unclear at this time (Banerjee
2011; Nelson 2011); further studies are underway to evaluate the
use of medications for treating DpD.
Index test(s)
A number of depression rating scales have been investigated as
possible tools to diagnose DpD (Alexopoulos 1988; Hancock
2009; Knapskog 2012; Muller-Thomsen 2005; Schreiner 2003;
Sunderland 1988).However, these scales forDpDdiffer in content
and mode of administration, and their comparative diagnostic
accuracy has not been synthesized todate.Wehave provided a table
summarizing key characteristics of these rating scales in Appendix
1.
Clinical pathway
Depression can be difficult to identify in individuals with demen-
tia, as they may not be able to communicate symptoms and be-
cause symptoms of dementia, such as apathy, can mimic depres-
sion. As a result, DpD can be both underdiagnosed (that is false
negatives), Volicer 2011, andoverdiagnosed (that is false positives),
Starkstein 2005, in clinical settings. The majority of individuals
with dementia will first be assessed by primary care providers such
as nurses or family physicians. People with dementia may present
for evaluation of potential depression with symptoms such as a
reported decrease in mood or loss of enjoyment in activities, or
with non-specific changes in sleep or appetite. Individuals with
milder severity of dementia may be able to self report symptoms
of depression similar to individuals without dementia. However,
individuals with more advanced dementia may not be able to re-
port these symptoms, and assessments incorporating clinician and
caregiver observations may be required to identify depression in
this population. In both community and long-term care settings,
depression rating scales may be used by primary care providers or
non-mental health clinicians to screen for DpD. Those individ-
uals who screen positive for possible DpD on these rating scales
may then go on to have further evaluation either by primary care
providers or be referred to specialists such as psychologists or psy-
chiatrists for further evaluation and confirmation of the diagnosis.
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The reference standard for the diagnosis of DpD is clinical exami-
nation and diagnosis by geriatric psychiatrists or psychologists us-
ing standardized diagnostic clinical criteria (American Psychiatric
Association 2000; Olin 2002). In some settings, screening posi-
tive on a depression rating scale may be used to initiate a referral
to mental health specialists, or primary care providers may decide
to initiate non-pharmacological or pharmacological treatment for
DpD based on the results of the depression rating scale and clinical
evaluation without referral to other services.
Alternative test(s)
Diagnosis of depression in dementia and other contexts relies on
clinical evaluation, and to date no validated alternative tests exist.
Rationale
There are gaps in the current knowledge base on practical strategies
for the diagnosis of DpD in routine clinical settings. The optimal
cut-points for diagnosing DpD on various depression rating scales
have not been consistently defined, and the comparative accuracy
of these different rating scales has not been described. In addi-
tion, the impact of factors such as patient characteristics, reference
standard used, setting (community/primary care, long-term care,
tertiary care), type and severity of dementia, and methods of scale
administration on the accuracy of depression scales remains un-
clear. To date, there are no published reviews on the accuracy of
depression rating scales for the diagnosis of DpD. Our search of
the PROSPERO registry and correspondence with the Cochrane
Dementia and Cognitive Improvement Group have not identified
any registered titles or protocols on this topic. To our knowledge,
our review will be the first to answer these important questions
regarding the accuracy of depression rating scales for diagnosing
DpD.
O B J E C T I V E S
To identify the accuracy of depression rating scales as screening
tools for detecting DpD and compare the diagnostic accuracy of
different depression rating scales for detectingMDDamong adults
with Alzheimer’s disease and related forms of dementia.
Secondary objectives
To examine factors that may impact on the accuracy of depression
rating scales that are used to diagnose depression. We will exam-
ine the reference standard used for verification of DpD, baseline
prevalence of DpD in the study population, age of the underlying
study population, gender of participants, type of dementia (any-
cause dementia versus Alzheimer’s disease), study setting (commu-
nity or primary care setting, long-term care, tertiary care setting),
and study country as potential sources of heterogeneity. We will
also evaluate the effects of using different cut-points of individual
depression rating scales on the diagnostic accuracy of the scales.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will follow general recommendations for the completion of
diagnostic test accuracy reviews (Cochrane 2013;Davis 2013).We
will focus our review on studies that assess all participants in the
study sample with both the index tests and reference standards for
DpD.We will include cross-sectional studies using any depression
rating scale in undifferentiated study populations diagnosed with
dementia.
Participants
Participants are individuals with a diagnosis of dementia us-
ing standardized diagnostic criteria (for example DSM-IV-TR
(American Psychiatric Association 2000), DSM-5 (American
Psychiatric Association 2013), ICD 9 or 10 (World Health
Organization 1992), or National Institute of Neurological Disor-
ders and Stroke - Alzheimer’s Disease and Related Disorders As-
sociation for Alzheimer’s disease (McKhann 1984)). We will in-
clude studies of participants with dementia due to Alzheimer’s
disease, vascular dementia (Roman 1993), mixed vascular and
Alzheimer’s disease dementia, and dementia with Lewy bodies
(McKeith 2005), as these are themost common forms of dementia
and there is significant overlap in pathology between these types of
dementia (Jellinger 2006). We will exclude less common forms of
dementias, such as Parkinson’s disease dementia, frontotemporal
dementia, progressive supranuclear palsy,multiple system atrophy,
or dementia due to general medical conditions such as HIV or
Huntington’s disease. In clinical practice, depression rating scales
may be used to diagnose DpD or as a screening tool to identify
individuals who if screened positive on the index test would go
on for further evaluation and confirmation of DpD using the ref-
erence standard. We will exclude studies that only conducted the
reference standard on the subgroup of the study population that
screened positive for DpD on the index tests.
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Index tests
The index tests are depression rating scales, including self report or
interviewer-based scales, which have been used to diagnose DpD.
We will not a priori restrict our review to any specific scales. Pre-
liminary literature searches have identified several scales which
have been used to diagnose DpD, including several generic depres-
sion rating scales (for example Hamilton Depression Rating Scale
(Lichtenberg 1992; Naarding 2002), Montgomery-Åsberg De-
pressionRating Scale (da Gloria 2012;Knapskog 2012; Leontjevas
2012), Geriatric Depression Scale (Bedard 2003; Debruyne 2009;
Feher 1992; Korner 2006; Lichtenberg 1992; Muller-Thomsen
2005; Schreiner 2003; Snow 2005), Nursing Observations Scale
for Geriatric Patients (Muller-Thomsen 2005), Patient Health
Questionnaire-9 (Hancock 2009), Beck Depression Inventory
(Beck 1961)) as well as rating scales specific to DpD (for example
Cornell Depression in Dementia Scale (Alexopoulos 1988; Barca
2010; da Gloria 2012; Knapskog 2012; Korner 2006; Leontjevas
2012; Muller-Thomsen 2005; Schreiner 2003) and Dementia
Mood Assessment Scale (Sunderland 1988)). These scales are con-
tinuous scales that rate the severity or frequency of symptoms of
depression. Various cut-points on these scales have been used as
a threshold to categorize individuals as being positive or nega-
tive for DpD (da Gloria 2012; Debruyne 2009; Knapskog 2012;
Leontjevas 2012). We have provided a summary of the character-
istics of these scales in Appendix 1.
Target conditions
Diagnostic criteria for major depressive disorder require the pres-
ence of either a depressed mood or a decreased interest in activities
for themajority of a two-week time period. Along with at least one
of these core symptoms, individuals must also experience at least
four additional symptoms including: changes in sleep, psychomo-
tor activities, appetite changes, feelings of guilt or worthlessness,
difficulties with concentration, decreased energy, or thoughts of
suicide or death. The individual must experience significant dis-
tress or dysfunction, and these symptoms must not be better ac-
counted for by the effects of a substance or a medical condition.
Reference standards
Major depressive disorder is a clinical diagnosis. The reference
standard for the diagnosis of DpD includes several depression
diagnostic criteria administered by a mental health professional.
The most commonly used depression diagnostic criteria are those
contained in the DSM. The criteria used in the various iterations
of DSM (for example III, IV-TR, 5) are relatively similar. These
diagnostic criteria for major depressive disorder can be used for
individualswith andwithout underlyingdementia, and their inter-
rater reliability is moderate to high (Brown 2001; Keller 1995;
Regier 1994; Spitzer 1979). Specific criteria for the diagnosis of
DpD have also been developed (Olin 2002). These criteria are
similar to the DSM-IV diagnostic criteria except that the core
criteria of a sad or depressed mood or reported lack of enjoyment
can be based on observations of the patient and fewer associated
symptoms are required (three total symptoms instead of five) (Olin
2002). Other depression diagnostic criteria, including the ICD 9
or 10, are similar to those of the DSM.
Search methods for identification of studies
Electronic searches
We will search MEDLINE (Ovid SP), EMBASE (Ovid SP),
CINAHL (EBSCOhost), LILACS (BIREME), BIOSIS Previews
(Thomson ReutersWeb of Science) andWeb of Science Core Col-
lection, includingConference ProceedingsCitation Index (Thom-
sonReutersWebof Science). SeeAppendix 2 for a proposedMED-
LINE search strategy plus an additional narrative on the search
strategy and process. We will apply no restrictions based on lan-
guage of publication, and potentially elgiible studies in languages
other than English will be translated.
The information specialist for the Cochrane Dementia and Cog-
nitive Improvement Group (Anna Noel-Storr) will perform the
initial searches.
Searching other resources
We will search the reference lists of relevant studies and reviews to
identify potentially relevant studies that may have been missed by
the electronic searches (Greenhalgh 2005; Horsely 2011). We will
use the related articles feature in electronic databases to identify
relevant studies. We will contact authors of included studies for
unpublished data that may be included in the analysis and to
identify unpublished study reports.
We will not perform handsearching, as there is little published
evidence of the benefits of handsearching for reports of diagnostic
test accuracy studies (Beynon 2013; Whiting 2011b).
Data collection and analysis
Selection of studies
The inclusion criteria for studies in this review are the following.
1. Study population with a diagnosis of dementia using
standardized criteria (e.g. DSM-IV-TR (American Psychiatric
Association 2000), DSM-5 (American Psychiatric Association
2013), ICD 9 or 10 (World Health Organization 1992),
National Institute of Neurological Disorders and Stroke -
Alzheimer’s Disease criteria (McKhann 1984)), vascular
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dementia (Roman 1993), mixed Alzheimer’s disease and vascular
dementia or dementia with Lewy bodies (McKeith 2005).
2. Reference standard diagnosis of major depressive disorder of
any severity or subtype diagnosed by a psychiatrist or other
qualified mental health practitioner according to either generic
diagnostic criteria (e.g. DSM-IV-TR, American Psychiatric
Association 2000) or specific diagnostic criteria for DpD (Olin
2002).
3. Index test including any depression rating scale used to
diagnose DpD; these scales may be generic depression rating
scales, in Knapskog 2012, Lichtenberg 1992, Muller-Thomsen
2005, and Schreiner 2003, or depression rating scales specific to
DpD (Alexopoulos 1988; Sunderland 1988); index and reference
test administered within two weeks.
We will exclude the following studies.
1. Case-control studies.
2. Studies where there is insufficient information to recreate
the 2x2 table of the number of true positives, false positives, false
negatives, and true negatives.
3. Studies that report depressive disorders other than major
depression.
4. Studies where participants have cognitive impairment that
does not meet the criteria for dementia.
Data extraction and management
Two review authors will independently extract information from
studies meeting the inclusion criteria. We will pilot, refine, and
thenuse a data extraction form (Appendix 3) to record information
from each included study. We will extract the following data.
1. Study design and setting.
2. Characteristics of the study population such as median/
mean age and range, sex, place of residence of participants,
educational status, cognitive testing (e.g. Mini Mental State
Exam score (Folstein 1975)), criteria used for diagnosis of
dementia, type of dementia (e.g. Alzheimer’s disease or all-cause
dementia), severity of underlying dementia (e.g. Clinical
Dementia Rating Scale, Hughes 1982, or Global Deterioration
Scale, Reisberg 1982, scores), prior history of depression and
other mental disorders.
3. Prevalence of DpD.
4. Depression rating scales along with the characteristics of
individuals administering each scale. We will also record the cut-
points used to identify participants as having a positive result for
DpD.
5. Reference standard criteria for the diagnosis of DpD along
with characteristics of the individuals administering the reference
standard.
6. Number of true positives, true negatives, false positives, and
false negatives or summary statistics that will enable their
derivation. We will use these values to create 2x2 tables for each
rating scale and enter the data into Review Manager version 5.3
(Review Manager 2014).
Assessment of methodological quality
We will assess the quality of studies using the QUADAS-2 tool,
which is recommended by The Cochrane Collaboration for ap-
praising the methodological quality of diagnostic accuracy stud-
ies (Whiting 2011a). The QUADAS-2 tool assesses risk of bias
in four domains: patient selection, index test, reference standard,
and participant flow and timing. Each domain is rated as being at
high, low, or unclear risk of bias based on responses to a series of
signalling questions. In addition to risk of bias, the tool also con-
siders issues of applicability related to patient selection, index test,
and reference standard. We have tailored the tool to our review
question and developed guidance on how to assess each signalling
question as shown in Appendix 4. We will summarize results of
the quality assessment in tables or figures or both.Wewill consider
the quality of the evidence when interpreting the findings of the
review and drawing conclusions.
Statistical analysis and data synthesis
We will analyse studies separately based on study setting: commu-
nity or primary care; long-term care or nursing homes; or tertiary
care. We will also separately analyze studies that used generic di-
agnostic criteria for MDD and those that used reference standard
criteria that are specific to DpD (Olin 2002).
We will create coupled forest plots of sensitivity and specificity for
each rating scale at one or more cut-points. Study-specific esti-
mates of sensitivity and specificity will also be plotted in receiver
operating characteristic (ROC) space. We will use these plots for
preliminary investigations of the data and to visually explore het-
erogeneity.
For each scale, if most studies report common cut-points, we will
perform meta-analysis by using the bivariate model to estimate
summary points (Chu 2006; Reitsma 2005). Alternatively, if stud-
ies report different cut-points, we will use the hierarchical sum-
mary ROC (HSROC) model to estimate SROC curves (Rutter
2001). Since sensitivity and specificty are useful summary mea-
sures for interpreting the consequences of test errors (false nega-
tives and false positives), we will quantify test performance from a
SROC curve by estimating sensitivity at points on the curve that
correspond to the lower quartile, median and upper quartile of the
specificities observed in the studies included in the meta-analysis.
If a study provides 2x2 tables for more than one cut-point, one ta-
ble will be selected at random for the HSROC analysis. However,
if several studies report data at several cut-points, we will consider
usingmethods that allow for such data (Dukic 2003;Hamza 2009;
Riley 2015). Given the complexity of hierarchical models, where
few studies are available we will simplify the models by removing
model parameters as has been recommended (Takwoingi 2015).
To formally compare the accuracy of the scales, we will add a
covariate indicating test type to a hierarchical model (bivariate
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or HSROC model) to assess differences in the accuracy of the
scales. We will assess the statistical significance of differences in
test performance using likelihood ratio tests to compare models
with and without the covariate terms. As comparative studies that
directly compare test accuracy are not often available (Takwoingi
2013), we plan to perform both indirect (include all available
studies) and direct test comparisons. Direct comparisons will be
performed as pairwise comparisons of studies that have compared
two scales head-to-head in the same study population.
Wewill use theNLMIXEDprocedure in the SAS software (version
9.4; SAS Institute, Cary, NC, USA) to fit HSROC models or the
meqrlogit command in Stata 14 (StataCorp, College Station, TX,
USA) to fit bivariate models.
Investigations of heterogeneity
We will perform investigations of heterogeneity using visual ex-
amination of forest plots and summary ROC plots in the first in-
stance.Where there is sufficient data, we will performmeta-regres-
sion by including each factor specified in our secondary objectives
as a covariate in a hierarchical model to determine its effect on test
accuracy.
Sensitivity analyses
Wewill repeat the primary meta-analyses excluding studies judged
as having a high risk of bias on the QUADAS-2 assessment for the
index test and reference standard domains.
Assessment of reporting bias
Little is known about the determinants and extent of publication
bias for test accuracy studies. Traditionally used methods for as-
sessing publication bias are not recommended for test accuracy
reviews. The most suitable approach for test accuracy reviews has
low power when there is heterogeneity (Deeks 2005). Since het-
erogeneity is expected in test accuracy reviews and is likely in this
review, we will not assess publication bias using any of the tests of
funnel plot asymmetry (Deeks 2005; van Enst 2014).
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A P P E N D I C E S
Appendix 1. Characteristics of depression rating scales
Scale Method of admin-
istration
Number of scale
items
Scoring of scale
items
Range and sug-
gested cut-points
Comments
Cornell Scale for
Depression in De-
mentia
Clinician interview
of participant and
informant
19 Unable to evaluate
0 = absent
1 =mild to intermit-
tent
2 = severe
0 to 28
≥ 9 screen positive
Specific to depres-
sion in dementia
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(Continued)
Dementia Mood
Assessment Scale
Caregiver re-
ports based on clin-
ician interview
24 0 = normal or mild
6 = severe or signif-
icant symptoms on
scale item
0 to 144
Cut-points not re-
ported
Contains both
mood and cognitive
assessments
Nurses’ Observa-
tion Scale for Geri-
atric Patients
Caregiver report 30 total, 5 items in
mood subscale
0 = all of the time
5 = never
0 to 150
0 to 25 for mood
subscale
≥ 10 suggestive of
depression
Geriatric
Depression Scale
Self report 30 Yes/No
Some items are re-
verse scored (e.g. Yes
can indicate possi-
ble sign of depres-
sion or absence of
depression depend-
ing on item)
0 to 30
≥6, ≥ 8, or ≥ 9
screen positive for
depression
Multiple versions
available, 30 item,
15 item
Hamilton Depres-
sion Rating Scale
Clinician interview 17 0 = absent
2 to 4 = severe
or significant symp-
toms (some items
are scored 0 to 2,
others 0 to 4)
0 to 52
≥ 8 considered pos-
itive for depression
Multiple versions
Mont-
gomery-Åsberg De-
pression Scale
Clinician interview 10 0 = absent or normal
6 = persistent or se-
vere symptoms
0 to 60
≥ 13 screen positive
for depression
BeckDepression In-
dex
Self report 21 0 = symptom absent
or no change
3 = severe or signifi-
cant
0 to 63
≥ 13 screen positive
for depression
Patient Health
Questionnaire
Self report 9 0 = absent
3
= symptom present
nearly everyday
0 to 27
≥ 8 to 11 suggestive
of depression
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Appendix 2. MEDLINE search strategy
1. exp Dementia/
2. dement*.mp.
3. alzheimer*.mp.
4. (VaD or VCI or “vascular cognit* impair*”).mp.
5. (lewy* adj2 bod*).mp.
6. (LBD or DLB).mp.
7. (FTD or FTLD or frontotemp* or “fronto-temp*”).mp.
8. or/1-7
9. (depression or depressed or depressive* or MDD).mp.
10. exp Depression/
11. exp Depressive Disorder, Major/
12. Depressive Disorder/
13. or/9-12
14. (hamilton adj6 depress*).mp.
15. (HDRS or “HDR scale” or HAM-D or HAMD or HAMD-17 or HAMD17).mp.
16. “hamilton scale questionnaire”.mp.
17. (hamilton adj3 “17-item”).mp.
18. (montgomery adj6 depress*).mp.
19. “montgomery-asberg”.mp.
20. MADRS.mp.
21. “montgomery scale”.mp.
22. “geriatric depression scale”.mp.
23. “geriatric depression scale-short”.mp.
24. GDS.mp.
25. GDS-15.mp.
26. “nurs* observation* scale for geriatric patients”.mp.
27. NOSGER.mp.
28. “patient* health questionnaire*”.mp.
29. (PHQ9 or PHQ-9).mp.
30. (PHQ adj6 depress*).mp.
31. (PHQ2 or PHQ-2).mp.
32. (“Cornell scale” adj4 depress*).mp.
33. CSDD.mp.
34. “Beck depression inventory”.mp.
35. BDI.mp.
36. “Beck inventory”.mp.
37. “Hospital Anxiety and Depression Scale”.mp.
38. HADS.mp.
39. (depress* adj2 score*).mp.
40. (depress* adj3 scale*).mp.
41. (depress* adj3 rating*).mp.
42. or/14-41
43. exp “sensitivity and specificity”/
44. “reproducibility of results”/
45. diagnos*.ti.
46. di.fs.
47. du.fs.
48. sensitivit*.ab.
49. specificit*.ab.
50. (ROC or “receiver operat*”).ab.
51. Area under curve/
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52. (“Area under curve” or AUC).ab.
53. sROC.ab.
54. accura*.ti,ab.
55. (likelihood adj3 (ratio* or function*)).ab.
56. ((true or false) adj3 (positive* or negative*)).ab.
57. ((positive* or negative* or false or true) adj3 rate*).ti,ab.
58. (“positive predictive value” or PPV).ab.
59. (“negative predictive value” or NPV).ab.
60. or/43-59
61. 8 and 42
62. 8 and 13 and 60
63. 61 or 62
Search narrative:
The MEDLINE search strategy above has been created to optimise sensitivity. The strategy utilises a number of concepts:
Concept A: lines 1 to 7 = health condition/s of interest
Concept B: lines 9 to 12 = target condition being measured by the index test/s/the index test/s
Concept C: lines 14 to 41 = index test/s
Concept D: lines 43 to 59 = methodological filter
Two combinations have been used:
A AND C
A AND B AND D
These have then be OR-ed
Appendix 3. Data extraction form for included studies
BIBLIOGRAPHIC DATA
Author/Year:
Title (Citation):
Country:
BASIC DEMOGRAPHIC AND CLINICAL DATA
Participant Recruitment:
Sampling Procedure:
Setting:
Number of Participants:
Gender:
Age:
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(Continued)
APOE4 carrier (%):
MMSE:
Education:
STUDY DESIGN:
TARGET CONDITION:
REFERENCE STANDARD(S)
INDEX TEST:
Method of the index test administration/scoring system:
Threshold(s) of index test in each study (cut-points used to define
a positive screen):
Length of time between administration of index test and reference
standard:
Number of disease positive (D+) and disease negative (D-) partic-
ipants:
Number of test positive (T+) and test negative (T-) participants:
DATA FOR 2X2 TABLE
True Positive (TP): Number of participants with index test+ MDD present
False Positive (FP): Number of participants with index test+ MDD absent
False Negative (FN): Number of participants with index test- MDD present
True Negative (TN): Number of participants with index test- MDD absent
Other relevant information: Sensitivity/Specificity/PPV/ NPV/LR+/LR-/AUC/Prevalence
Data extracted by:
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Appendix 4. QUADAS-2 Assessment
Domain Participant selection Index test Reference standard Flow and timing
Description Describe methods
of participant selection:
describe included partic-
ipants (prior testing, pre-
sentation, intended use
of index test and setting)
Describe the index test
and how it was con-
ducted and interpreted
Describe the reference
standard and how it
was conducted and in-
terpreted
De-
scribe any participants
who did not receive the
index test(s) and/or ref-
erence standard or who
were excluded from the
2x2 table (refer to flow
diagram); describe the
time interval and any in-
terventions between in-
dex test(s) and reference
standard
Signalling questions
(yes/no/unclear)
Was a consecutive or ran-
dom sample of patients
enrolled?
Was a case-control de-
sign avoided?
Did the study avoid in-
appropriate exclusions?
Were the index test re-
sults interpreted without
knowledge of the results
of the reference stan-
dard?
If a threshold was used,
was it prespecified?
Is the reference standard
likely to correctly classify
the target condition?
Were the reference stan-
dard results interpreted
without knowledge of
the results of the index
test?
Was there an appropri-
ate interval between in-
dex test(s) and reference
standard?
Did all participants re-
ceive the same reference
standard?
Were all participants in-
cluded in the analysis?
Risk of bias:
(high/low/unclear)
Could the selection of
participants have intro-
duced bias?
Could the conduct or in-
terpretation of the in-
dex test have introduced
bias?
Could the reference stan-
dard, its conduct, or its
interpretation have in-
troduced bias?
Could the patient flow
have introduced bias?
Concerns regarding ap-
plicability:
(yes/no/unclear)
Are there concerns that
the included participants
do not match the review
question?
Are there concerns that
the index test, its con-
duct, or interpretation
differ from the review
question?
Are there concerns that
the target condition as
defined by the reference
standard does not match
the review question?
-
Anchoring statements to assist with assessment of risk of bias
Domain 1: Participant selection
Risk of bias: could the selection of participants have introduced bias? (high, low, unclear)
Signalling question 1: Was a consecutive or random sample of patients enrolled?
We will score ’yes’ for studies that used either a random or consecutive sampling of individuals with dementia; ’no’ if a convenience
sample is used; and ’unclear’ if the study did not specify the method for participant selection or if the information on this item was not
provided.
Signalling question 2: Was a case-control design avoided?
We will exclude studies using a case-control design; we will include only studies rated ’yes’ on this question and exclude all studies rated
’no’. We will exclude case-control studies because major depressive disorder is commonly underestimated, and use of a case-control
study design may overestimate the diagnostic accuracy of tests by only including individuals with more severe major depressive disorder.
Signalling question 3: Did the study avoid inappropriate exclusions?
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We will score this as ’yes’ if all individuals with dementia who would potentially be eligible for assessment with depression rating scales
are included. We will rate this item as ’no’ if only a sample of individuals are selected for assessment with the index and reference test
based on some other screening criteria prior to receiving the index or reference test (that is screening positive on a brief assessment
before undergoing further assessment with index test and reference standard). We will score this item as ’unclear’ if there is insufficient
information available to determine a rating.
Applicability: are there concerns that the included participants do not match the review question?
We will rate this item as ’no’ if the study examined a population of individuals with dementia using both the index test and reference
standard, since this would ensure the individuals were more representative of the target population. We will rate this item as ’yes’ if
only a subpopulation of the entire study is evaluated or if the study evaluates a population such as a psychiatric inpatient unit or mental
health setting where the prevalence of major depressive disorder among individuals with dementia would be expected to be higher than
in other settings (for example community or long-term care). We will rate this item as ’unclear’ if there is insufficient information to
determine the applicablity.
Domain 2: Index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias? (high/low/unclear)
Signalling question 1: Were the index test results interpreted without knowledge of the reference standard?
We will rate this item as ’yes’ if the term ’blinded’ was used to describe the process by which the results of the reference standard were
performed with respect to knowledge of the index depression rating scales. We will also rate this item as ’yes’ if it is clear in the study
that the individuals who completed the index tests were different from those who completed the reference standards (that is research
assistants completing the index tests and psychiatrists completing the index test). We will rate this item as ’no’ if the same individual
administered the test or if knowledge of the results of the index tests was reported to be known to the individual administering the
reference standard. We will rate this item as ’unclear’ if there is insufficient information available to complete a rating for this item.
Signalling question 2: Were the index test thresholds prespecified?
Wewill rate this item as ’yes’ if the thresholds for determining major depressive disorder status were prespecified or if multiple thresholds
were examined in the study; ’no’ if only a single threshold was defined post-hoc based on the results of the study; and ’unclear’ if there
is insufficient information to make a determination about this item.
Were sufficient data on depression rating scale application given for the test to be repeated in an independent study?.
We will score this as ’yes’ if the background of the person administering the index test (for example trained research assistant, physician,
psychologist) and the sources of information used for the test (for example participant only or participant and other sources of
information such as family members or staff ) were reported; ’no’ if information on both of these items was not reported; and ’unclear’
if there was insufficient information to make a determination.
Applicability: are there concerns that the index test, its conduct, or interpretation differ from the review question? (no, yes,
unclear)
We will assign ’no’ if the depression rating scales were administered to individuals with dementia at risk for depression and conducted
according to standard procedures recommended for the scale. We will assign ’yes’ if the depression rating scale is conducted in a
fashion that is significantly different from accepted procedures recommended for conducting the test, or ’unclear’ if there is insufficient
information.
Domain 3: Reference standard
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias? (high, low, unclear)
Signalling question 1: Is the reference standard likely to correctly classify the target condition?
We will assign a score of ’yes’ if the study used one of the validated reference standards listed in the protocol and if the reference standard
was administered by a mental health professional (for example psychiatrist, geriatric psychiatrist, psychologist). We will rate studies
as ’no’ if a validated reference standard was either not used in the study or if it was administered by people other than mental health
professionals. We will rate studies as ’unclear’ where there is insufficient evidence to determine this item.
Signalling question 2: Were the reference standard results interpreted without knowledge of the results of the index test?
We will assign a score of ’yes’ if the study reported that individuals administering the reference test were either blinded to the results of
the index test or if the individuals administering the index and reference tests were different individuals. We will assign scores of ’no’ if
it is clear that the individuals administering the reference standard were aware of the results of the index test or if the same individual
administered both the index and reference tests.
Signalling question 3:Was sufficient information on themethod of depression assessment given for the assessment to be repeated in an independent
study?
Wewill rate this item as ’yes’ if the background of the person administering the reference standard was reported (for example psychiatrist)
and themethod for obtaining the diagnosis (for example clinical interview)was reported.Wewill rate this item as ’no’ if who administered
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the reference standard or what information was utilized to determine the reference standard was not clearly identified. We will assign
’unclear’ if there is insufficient information to determine this item.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the review question?
(no, yes, unclear)
If the reference standard was applied to an unspecified sample of individuals with dementia, we will assign a score of ’no’; if the reference
standard was only applied to subgroup of the study sample (for example only those with known depressive symptoms), we will rate this
as ’yes’.
Domain 4: Patient flow and timing (Figure 1)
Risk of bias: could the patient flow have introduced bias? (high, low, unclear)
Signalling question 1: Was there an appropriate interval between the index test and reference standard?
Depression can resolve or remit over time, although it tends to be relatively stable over short periods of time. We will rate this item
as ’yes’ if the index and reference tests were completed within a two-week period, ’no’ if a period of greater than two weeks elapsed
between administration of the index and reference tests, and ’unclear’ if the interval between the the index test and reference standard
was not specified.
Signalling question 2: Did all participants receive the same reference standard?
We will rate this item as ’yes’ if all individuals who received the index test also received the reference standard and ’no’ if only a sample
of individuals that received the index test received the reference standard (for example only those who screened positive on the index
test later received the reference standard). We will assign ’unclear’ if the proportion of individuals who received both the index and
reference standard was not clear.
Signalling question 3: Were all participants included in the final analysis?
We anticipate that dropouts will be minimal in the cross-sectional studies included in our review. We will assign a score of ’yes’ if
90% or greater of individuals who received the index test later had the reference standard, ’no’ if this proportion is less than 90%, and
’unclear’ where there is insufficient information to make a determination.
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